Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma



Status:Recruiting
Conditions:Lung Cancer, Lung Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/22/2019
Start Date:November 3, 2017
End Date:June 1, 2020

Use our guide to learn which trials are right for you!

A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma

This phase I pilot trial studies how well atezolizumab, pemetrexed disodium, cisplatin, and
surgery with or without radiation therapy in treating patients with stage I-III pleural
malignant mesothelioma. Immunotherapy with monoclonal antibodies, such as atezolizumab, may
help the body's immune system attack the cancer, and may interfere with the ability of tumor
cells to grow and spread. Pemetrexed disodium may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin,
work in different ways to stop the growth of tumor cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Giving atezolizumab,
pemetrexed disodium, and cisplatin before surgery may make the tumor smaller and reduce the
amount of normal tissue that needs to be removed. Giving atezolizumab after surgery may kill
any remaining tumor cells.

PRIMARY OBJECTIVES:

I. To evaluate if the regimen of neoadjuvant cisplatin-pemetrexed disodium
(pemetrexed)-atezolizumab, surgery +/- radiation, then maintenance atezolizumab is feasible
and safe for patients with resectable malignant pleural mesothelioma.

SECONDARY OBJECTIVES:

I. To evaluate progression free survival (both by Response Evaluation Criteria in Solid
Tumors [RECIST] 1.1 and also using a modified RECIST for pleural tumors) in patients with
resectable malignant pleural mesothelioma treated with a regimen of neoadjuvant
cisplatin-pemetrexed-atezolizumab, surgery +/- radiation, followed by one year of maintenance
atezolizumab.

II. To evaluate overall survival in patients with resectable malignant pleural mesothelioma
treated with a regimen of neoadjuvant cisplatin-pemetrexed-atezolizumab, surgery +/-
radiation, followed by one year of maintenance atezolizumab.

III. To evaluate response rate (confirmed and unconfirmed, complete and partial, both by
RECIST 1.1 and also using a modified RECIST for pleural tumors) in the subset of this patient
population with measurable disease.

TRANSLATIONAL MEDICINE OBJECTIVES:

I. To evaluate the association between immunohistochemical (IHC) expression of PD-L1 in
tumors and clinical outcomes in mesothelioma patients treated with trimodality/bimodality
therapy including atezolizumab (anti-PD-L1).

II. To evaluate the association between expression of immune-related genes identified by
Immune Nanostring (depending on ribonucleic acid [RNA] availability) and clinical outcomes in
mesothelioma patients treated with trimodality/bimodality therapy including atezolizumab.

III. To evaluate the association between multiplex immunofluorescence (IF) of up to 10 immune
markers in two panels and clinical outcomes in mesothelioma patients treated with
trimodality/bimodality therapy including atezolizumab.

OUTLINE:

NEOADJUVANT: Patients receive atezolizumab intravenously (IV) over 60-90 minutes, pemetrexed
disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Treatment repeats every
21 days for 4 courses in the absence of disease progression or unexpected toxicity.

SURGERY: Patients undergo extrapleural pneumonectomy (EPP) or pleurectomy/decortication (PD).
After 4-8 weeks after EPP, patients may receive radiation therapy.

MAINTENANCE: Beginning 6-8 weeks after completion of either PD or radiation (post-EPP),
patients receive atezolizumab IV over 60 minutes on day 1. Courses repeat every 21 days for
up to 1 year in the absence of disease progression or unexpected toxicity.

After completion of study treatment, patients are followed up for up to 3 years.

Inclusion Criteria:

- STEP 1: NEOADJUVANT

- Patient must have stage I-III malignant pleural mesothelioma that is deemed resectable
and must be planning to undergo pleurectomy decortication (P/D) or extrapleural
pneumonectomy (EPP)

- Patient must have epithelioid or biphasic histology (sarcomatoid histology is
excluded); histologic diagnosis and typing of mesothelioma will require at least a
core needle biopsy or surgical biopsy of the pleura via thoracoscopy and small
thoracotomy; cytology only will not be regarded as sufficient for the diagnosis

- Patient must have computed tomography (CT) chest/abdomen/pelvis with contrast or
fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/CT scan performed within
28 days prior to step 1 registration

- Patients must have non-measurable or measurable disease documented by CT or magnetic
resonance imaging (MRI); the CT from a combined PET/CT may be used to document only
non-measurable disease unless it is of diagnostic quality; measurable disease must be
assessed within 28 days prior to step 1 registration; non-measurable disease must be
assessed within 42 days prior to step 1 registration; all disease must be assessed and
documented on the RECIST 1.1 and modified RECIST baseline tumor assessment form

- Patient must have undergone extended surgical staging including mediastinoscopy or
endobronchial ultrasound; at minimum, samples must be obtained from the mediastinal
stations 4R, 7 (subcarinal), and 4L; this surgical staging must be performed within 42
days prior to step 1 registration; patient must be T1-3 and N0-N2 (single station)

- Patient must undergo video-assisted thoracoscopic surgery and diagnostic laparoscopy
within 28 days prior to step 1 registration; patients must undergo the diagnostic
laparoscopy to rule out peritoneal disease spread

- Patient must have consultation with a surgeon within 21 days prior to step 1
registration; the surgeon must confirm that the patient's disease is resectable by
pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP) and that the
patient is an appropriate candidate for the surgical procedures

- Patient must not have had prior immunotherapy or chemotherapy for malignant pleural
mesothelioma

- Patient must have Zubrod performance status 0 or 1 documented within 28 days prior to
step 1 registration

- Patients requiring hearing aids or reporting hearing loss must have audiogram
performed within 28 days prior to step 1 registration; if audiogram is performed,
patient must not have hearing impairment >= Common Terminology Criteria for Adverse
events (CTCAE) grade 2

- Patient must have not had any major surgery or radiation within 28 days prior to step
1 registration; diagnostic thoracotomies and laparoscopies are not considered major
surgeries

- Patients must not have any anticancer therapy or investigational agent (within 28 days
prior to step 1 registration)

- Absolute neutrophil count (ANC) >= 1,500/mcl (documented within 28 days prior to step
1 registration)

- Hemoglobin >= 9 g/dl (documented within 28 days prior to step 1 registration)

- Platelets >= 100,000/mcl (documented within 28 days prior to step 1 registration)

- Creatinine =< 1.5 x upper limit of normal (ULN) (documented within 28 days prior to
step 1 registration)

- Creatinine clearance >= 45 ml/min (documented within 28 days prior to step 1
registration)

- Total bilirubin =< 1.5 x upper limit of normal (ULN) (within 28 days prior to step 1
registration)

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (within
28 days prior to step 1 registration)

- No other prior malignancy is allowed except for the following: adequately treated
basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
stage I or II cancer from which the patient is currently in complete remission, or any
other cancer from which the patient has been disease free for three years

- Patient must not be pregnant or nursing; women of reproductive potential and men must
have agreed to use an effective contraceptive method for the duration of study
treatment and for 5 months (150 days) after the last dose of atezolizumab; a woman is
considered to be of "reproductive potential" if she has had menses at any time in the
preceding 12 consecutive months; in addition to routine contraceptive methods,
"effective contraception" also includes heterosexual celibacy and surgery intended to
prevent pregnancy (or with a side effect of pregnancy prevention) defined as a
hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any
point a previously celibate patient chooses to become heterosexually active during the
time period for use of contraceptive measures outlined in the protocol, he/she is
responsible for beginning contraceptive measures

- Patient must NOT have a history of severe allergic, anaphylactic, or other
hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins

- Patient must NOT have a known hypersensitivity or allergy to biopharmaceuticals
produced in Chinese hamster ovary cells or any component of the atezolizumab
formulation

- Patients must not have severe infections within 28 days prior to step 1 registration,
including but not limited to hospitalization for complications of infection,
bacteremia, or severe pneumonia

- Patients must not have active autoimmune disease that has required systemic treatment
in past two years (i.e., with use of disease modifying agents, corticosteroids or
immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or
physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency,
etc.) is not considered a form of systemic treatment; autoimmune diseases include, but
are not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory
bowel disease, vascular thrombosis associated with antiphospholipid syndrome,
Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome,
multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis;
this protocol includes an immunotherapy agent which can precipitate known autoimmune
diseases

- Patients must not have undergone prior allogeneic bone marrow transplantation or prior
solid organ transplantation

- Patient must not have active tuberculosis

- Patient must not have history of idiopathic pulmonary fibrosis, pneumonitis (including
drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic
organizing pneumonia, etc.), or evidence of active pneumonitis; this protocol includes
an immunotherapy agent which can precipitate known pneumonitis

- Patient must not have active (chronic or acute) hepatitis B virus (HBV) infection as
evidenced by testing performed within 28 days prior to registration; patients with
past or resolved HBV infection are eligible; active HBV is defined as having a
positive hepatitis B surface antigen (HBsAg) test; past or resolved HBV is defined as
having a negative HBsAG test and a positive total hepatitis B core antibody (HBcAb)
test; patient must not have active hepatitis C virus (HCV) infection as evidenced by
testing performed within 28 days prior to registration; active HCV is defined as
having a positive HCV antibody test followed by a positive HCV RNA test

- Patient must NOT have a known positive test for human immunodeficiency virus (HIV);
patients do not need to be screened for HIV; patients with HIV are excluded

- Patient must not have significant cardiovascular disease, such as New York Heart
Association cardiac disease (class II or greater), myocardial infarction within 3
months prior to initiation of treatment, unstable arrhythmias, or unstable angina
given the higher risks associated with surgical resection

- Patient must not receive live, attenuated influenza vaccine within 4 weeks prior to
registration or at any time during the study and until 5 months after the last dose of
atezolizumab

- Patient must be willing to have tissue specimens submitted for translational medicine
studies

- Patient must be offered the opportunity to participate in tissue and blood banking for
future studies

- Patient must be informed of the investigational nature of this study and must sign and
give written informed consent in accordance with institutional and federal guidelines

- As a part of the Oncology Patient Enrollment Network (OPEN) registration process, the
treating institution's identity is provided in order to ensure that the current
(within 365 days) date of institutional review board approval for this study has been
entered in the system

- STEP 2: SURGERY

- Patient must have a CT of chest/abdomen with contrast or FDG-PET/CT scan within 28
days prior to step 2 registration; patients must not have evidence of progression per
RECIST 1.1 or modified RECIST for pleural tumors

- Patients planning to receive EPP must also be evaluated for appropriateness of
radiation therapy (RT) by a radiation oncologist within 14 days prior to step 2
registration

- Patients must have a Zubrod performance status of 0-1 documented within 28 days prior
to step 2 registration

- Patients must have postoperative predicted forced expiratory volume in 1 second (FEV1)
> 35% prior to surgery obtained within 28 days prior to step 2 registration

- Patients must have postoperative predicted carbon monoxide diffusing capability (DLCO)
> 35% prior to surgery obtained within 28 days prior to step 2 registration

- Patients must have postoperative oxygen consumption (VO2) max > 15 ml/kg/min prior to
surgery obtained within 28 days prior to step 2 registration

- Patient must have received at least two cycles of triplet neoadjuvant therapy (all
three drugs) during step 1

- Patient must be registered to step 2 no less than 21 days and no more than 90 days
after the end of their final cycle of neoadjuvant therapy

- STEP 3: MAINTENANCE

- Patient must have received either P/D or EPP and must have recovered from all effects
of surgery with adequate wound healing; patients who received radiation therapy (RT)
must be registered to step 3 within 28 days after discontinuing RT; patients who did
not receive RT must be registered to step 3 within 56 days after surgery

- Patient must have a CT of chest/abdomen/pelvis with contrast or FDG-PET/CT scan within
28 days prior to step 3 registration; patient must not have evidence of progression
per RECIST 1.1 or modified RECIST for pleural tumors

- Patient may have discontinued RT early due to toxicity or other reasons

- Patients must have a Zubrod performance status of 0-1 documented within 28 days prior
to step 3 registration

- ANC > 1,500/mcl (documented within 28 days prior to step 3 registration)

- Hemoglobin > 9 g/dl (documented within 28 days prior to step 3 registration)

- Platelets > 100,000/mcl (documented within 28 days prior to step 3 registration)

- Creatinine < 1.5 x ULN (documented within 28 days prior to step 3 registration)

- Total bilirubin =< 1.5 x upper limit of normal (ULN) (within 28 days prior to step 3
registration)

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (within
28 days prior to step 3 registration)
We found this trial at
150
sites
Rochester, Minnesota 55905
Principal Investigator: Helen J. Ross
Phone: 855-776-0015
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Richard D. Hall
Phone: 434-243-6303
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
(206) 667-5000
Principal Investigator: Bernardo Haddock Lobo Goulart
Phone: 800-804-8824
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Bernardo Haddock Lobo Goulart
Phone: 800-804-8824
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
?
mi
from
Ames, IA
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
?
mi
from
Ames, IA
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Anaconda, MT
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Suparna Mantha
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Principal Investigator: Mehmet S. Copur
Phone: 502-350-5700
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
?
mi
from
Billings, MT
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: James L. Wade
Phone: 800-793-2262
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Boise, ID
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
?
mi
from
Bonne Terre, MO
Click here to add this to my saved trials
Boone, Iowa 50036
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
?
mi
from
Boone, IA
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
Bryan, Texas 77802
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bryan, TX
Click here to add this to my saved trials
Burien, Washington 98166
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Burien, WA
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Caldwell, ID
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
309-647-5240
Principal Investigator: James L. Wade
Phone: 800-793-2262
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Canton, IL
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: Bryan A. Faller
Phone: 573-651-5550
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Carbondale, Illinois 62902
Principal Investigator: Bryan A. Faller
Phone: 618-457-5200
?
mi
from
Carbondale, IL
Click here to add this to my saved trials
Carterville, Illinois 62918
Principal Investigator: Bryan A. Faller
Phone: 618-985-3333
?
mi
from
Carterville, IL
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: James L. Wade
Phone: 800-793-2262
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Carthage, IL
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Centralia, IL
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: John M. Wrangle
Phone: 843-792-9321
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Chattanooga, Tennessee 37404
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Cincinnati, Ohio 45220
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45242
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45247
Principal Investigator: Mehmet S. Copur
Phone: 513-451-4033
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45255
Principal Investigator: Mehmet S. Copur
Phone: 513-451-4033
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Clive, Iowa 50325
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Clive, IA
Click here to add this to my saved trials
12495 University Ave
Clive, Iowa 50325
(515) 358-9700
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Mercy Cancer Center - West Lakes When it comes to cancer care, there
?
mi
from
Clive, IA
Click here to add this to my saved trials
Cody, Wyoming 82414
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
?
mi
from
Cody, WY
Click here to add this to my saved trials
Coeur d'Alene, Idaho 83814
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
6001 E Woodmen Rd
Colorado Springs, Colorado 80923
(719) 776-5000
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Penrose-Saint Francis Healthcare Founded by the Sisters of St. Francis and the Sisters of Charity,...
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Colorado Springs, Colorado 80907
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Corbin, Kentucky 40701
Principal Investigator: Mehmet S. Copur
?
mi
from
Corbin, KY
Click here to add this to my saved trials
Council Bluffs, Iowa 51503
Principal Investigator: Mehmet S. Copur
?
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
Creston, Iowa 50801
Principal Investigator: Mehmet S. Copur
Phone: 641-782-3693
?
mi
from
Creston, IA
Click here to add this to my saved trials
Danville, Illinois 61832
Principal Investigator: Suparna Mantha
Phone: 800-446-5532
?
mi
from
Danville, IL
Click here to add this to my saved trials
2300 N Edward St
Decatur, Illinois 62526
(217) 876-8121
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
?
mi
from
Decatur, IL
Click here to add this to my saved trials
210 West McKinley Avenue
Decatur, Illinois 62526
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Decatur, IL
Click here to add this to my saved trials
2525 S Downing St
Denver, Colorado 80210
(303) 778-1955
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Porter Adventist Hospital Founded in 1930, Porter Adventist Hospital has provided people throughout Denver and...
?
mi
from
Denver, CO
Click here to add this to my saved trials
Des Moines, Iowa 50314
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
1111 6th Ave
Des Moines, Iowa 50314
(515) 247-3121
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Mercy Medical Center - Des Moines Mercy Medical Center
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
Durango, Colorado 81301
Principal Investigator: Mehmet S. Copur
Phone: 303-777-2663
?
mi
from
Durango, CO
Click here to add this to my saved trials
Durango, Colorado 81301
Principal Investigator: Mehmet S. Copur
Phone: 303-777-2663
?
mi
from
Durango, CO
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Effingham, IL
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: Suparna Mantha
Phone: 800-446-5532
?
mi
from
Effingham, IL
Click here to add this to my saved trials
Enumclaw, Washington 98022
Principal Investigator: Mehmet S. Copur
?
mi
from
Enumclaw, WA
Click here to add this to my saved trials
101 S Major St
Eureka, Illinois 61530
309-467-2371
Principal Investigator: James L. Wade
Phone: 800-793-2262
Illinois CancerCare - Eureka Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Eureka, IL
Click here to add this to my saved trials
Federal Way, Washington 98003
Principal Investigator: Mehmet S. Copur
Phone: 253-944-8100
?
mi
from
Federal Way, WA
Click here to add this to my saved trials
Fort Dodge, Iowa 50501
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
?
mi
from
Fort Dodge, IA
Click here to add this to my saved trials
Galesburg, Illinois 61401
Principal Investigator: Bryan A. Faller
Phone: 309-344-2831
?
mi
from
Galesburg, IL
Click here to add this to my saved trials
3315 N Seminary St
Galesburg, Illinois 61401
309-344-9269
Principal Investigator: James L. Wade
Phone: 800-793-2262
Illinois CancerCare - Galesburg Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Galesburg, IL
Click here to add this to my saved trials
Golden, Colorado 80401
Principal Investigator: Mehmet S. Copur
Phone: 303-777-2663
?
mi
from
Golden, CO
Click here to add this to my saved trials
Grand Island, Nebraska 68803
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Grand Island, NE
Click here to add this to my saved trials
1117 29th St S
Great Falls, Montana 59405
(406) 771-7300
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Benefis Healthcare- Sletten Cancer Institute Benefis Hospitals has 516 beds at its two campuses (that...
?
mi
from
Great Falls, MT
Click here to add this to my saved trials
1400 29th Street South
Great Falls, Montana 59405
406-454-2171
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Great Falls Clinic Founded in 1917, the Great Falls Clinic is the fourth oldest medical...
?
mi
from
Great Falls, MT
Click here to add this to my saved trials
Helena, Montana 59601
Principal Investigator: Benjamin T. Marchello
?
mi
from
Helena, MT
Click here to add this to my saved trials
Hixson, Tennessee 37343
Principal Investigator: Mehmet S. Copur
?
mi
from
Hixson, TN
Click here to add this to my saved trials
Hot Springs, Arkansas 71913
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Anne S. Tsao
Phone: 713-566-5000
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Anne S. Tsao
Phone: 877-312-3961
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77094
Principal Investigator: Anne S. Tsao
Phone: 877-632-6789
?
mi
from
Houston, TX
Click here to add this to my saved trials
Jacksonville, Florida 32207
Principal Investigator: John H. Vu
Phone: 904-202-7051
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Jefferson, Iowa 50129
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
?
mi
from
Jefferson, IA
Click here to add this to my saved trials
Jefferson City, Missouri 65109
Principal Investigator: Bryan A. Faller
Phone: 573-632-4814
?
mi
from
Jefferson City, MO
Click here to add this to my saved trials
310 Sunnyview Ln
Kalispell, Montana 59901
(406) 752-5111
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Kalispell Regional Medical Center Nestled in the beautiful Flathead Valley of Northwestern Montana, Kalispell Regional...
?
mi
from
Kalispell, MT
Click here to add this to my saved trials
Kearney, Nebraska 68845
Principal Investigator: Mehmet S. Copur
Phone: 308-865-2303
?
mi
from
Kearney, NE
Click here to add this to my saved trials
Kearney, Nebraska 68847
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Kearney, NE
Click here to add this to my saved trials
205 Tenney St
Kewanee, Illinois 61443
309-852-0596
Principal Investigator: James L. Wade
Phone: 800-793-2262
Illinois CancerCare - Kewanee Clinic Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer...
?
mi
from
Kewanee, IL
Click here to add this to my saved trials
Lakewood, Colorado 80228
Principal Investigator: Mehmet S. Copur
Phone: 303-777-2663
?
mi
from
Lakewood, CO
Click here to add this to my saved trials
Lakewood, Colorado 80228
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Lakewood, CO
Click here to add this to my saved trials
Lakewood, Washington 98499
Principal Investigator: Mehmet S. Copur
Phone: 253-985-6110
?
mi
from
Lakewood, WA
Click here to add this to my saved trials
325 Maine Street
Lawrence, Kansas 66044
(785) 505-5000
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Lawrence Memorial Hospital Lawrence Memorial Hospital (LMH), in collaboration with its medical staff, is dedicated...
?
mi
from
Lawrence, KS
Click here to add this to my saved trials
Lawton, Oklahoma 73505
Principal Investigator: Vipul Pareek
Phone: 877-231-4440
?
mi
from
Lawton, OK
Click here to add this to my saved trials
Lexington, Kentucky 40504
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Lexington, Kentucky 40509
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Lincoln, Nebraska 68510
Principal Investigator: Mehmet S. Copur
Phone: 402-483-2827
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
7700 S Broadway
Littleton, Colorado 80122
(303) 730-8900
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Littleton Adventist Hospital On April 3, 1989 Littleton Adventist Hospital opened its doors to the...
?
mi
from
Littleton, CO
Click here to add this to my saved trials
1001 Saint Joseph Lane
London, Kentucky 40741
Principal Investigator: Mehmet S. Copur
Phone: 888-823-5923
?
mi
from
London, KY
Click here to add this to my saved trials
Longmont, Colorado 80501
Principal Investigator: Mehmet S. Copur
Phone: 303-777-2663
?
mi
from
Longmont, CO
Click here to add this to my saved trials
1950 Mountain View Ave
Longmont, Colorado 80501
(303) 651-5111
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Longmont United Hospital Healthcare at Longmont United Hospital is more than treating a patient's physical...
?
mi
from
Longmont, CO
Click here to add this to my saved trials
Louisville, Kentucky 40202
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Louisville, Kentucky 40215
Principal Investigator: Mehmet S. Copur
Phone: 502-587-4108
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Louisville, Kentucky 40245
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Louisville, KY
Click here to add this to my saved trials
501 E Grant
Macomb, Illinois 61455
309-833-3503
Principal Investigator: James L. Wade
Phone: 800-793-2262
Illinois CancerCare - Macomb Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Macomb, IL
Click here to add this to my saved trials
Marshalltown, Iowa 50158
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
?
mi
from
Marshalltown, IA
Click here to add this to my saved trials
Mattoon, Illinois 61938
Principal Investigator: Suparna Mantha
Phone: 800-446-5532
?
mi
from
Mattoon, IL
Click here to add this to my saved trials
Meridian, Idaho 83642
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Meridian, ID
Click here to add this to my saved trials
Missoula, Montana 59801
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Missoula, MT
Click here to add this to my saved trials
Nassau Bay, Texas 77058
Principal Investigator: Anne S. Tsao
Phone: 877-312-3961
?
mi
from
Nassau Bay, TX
Click here to add this to my saved trials
New Orleans, Louisiana 70121
Principal Investigator: Suma P. Satti
Phone: 504-703-8712
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
940 NE 13th St
Oklahoma City, Oklahoma 73190
(405) 271-6458
Principal Investigator: Vipul Pareek
Phone: 405-271-8777
University of Oklahoma Health Sciences Center The OU Health Sciences Center is composed of seven...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Omaha, Nebraska 68122
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Omaha, NE
Click here to add this to my saved trials
7500 Mercy Rd
Omaha, Nebraska 68124
(402) 398-6060
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Alegent Health Bergan Mercy Medical Center Alegent Creighton Health is now CHI Health, giving you...
?
mi
from
Omaha, NE
Click here to add this to my saved trials
16901 Lakeside Hills Ct
Omaha, Nebraska 68130
(402) 717-8000
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Alegent Health Lakeside Hospital Welcome to Lakeside Hospital, West Omaha's only full-service hospital. We believe...
?
mi
from
Omaha, NE
Click here to add this to my saved trials